The Psyence Biomedical Ltd. (PBM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Psyence BioMed files under Form 20-F and furnishes interim and event-driven information on Form 6-K, as reflected in the available filings.
Through these filings, investors can review unaudited interim condensed consolidated financial statements and accompanying Management’s Discussion and Analysis for specified periods, as referenced in a Form 6-K describing financial statements for the three and six months ended September 30 in certain years. Exhibits to Form 6-K reports may also include press releases, equity incentive plan documents, and details of material agreements.
Some PBM filings describe corporate and governance developments, such as changes in executive roles, appointments to the Board of Directors, and amendments to capital arrangements. For example, a Form 6-K outlines the appointment of the company’s Chief Financial Officer to the Board and the entry into an amendment to a Common Stock Purchase Agreement with an investor, providing context on the company’s access to capital.
Other Form 6-K submissions incorporate press releases on topics such as clinical trial progress, strategic investments in PsyLabs, and share-related actions. These filings may be incorporated by reference into the company’s shelf registration statements on Form F-3, as indicated in the text of certain reports.
On Stock Titan, PBM filings are updated as new documents are posted to the SEC’s EDGAR system. AI-powered summaries can help explain key elements of lengthy filings, highlight changes in capital structure, and clarify the implications of agreements or governance updates. Users can quickly scan for items such as interim financial results, capital management disclosures, and material contracts, and can also monitor how press releases referenced in filings align with the company’s broader clinical and strategic narrative.
Psyence Biomedical Ltd. (PBM), through its wholly owned subsidiary Psyence Biomed II Corp., completed an additional US$2,599,896 investment in PsyLabs after both milestones tied to its backstop commitment were achieved. The subsidiary subscribed for 1,014 PsyLabs ordinary shares at US$2,564 per share, at the financing round’s US$54 million pre-money equity valuation. PBM held approximately 41.13% of PsyLabs’ issued and outstanding shares immediately before the investment; following completion and giving effect to a share exchange that closed October 1, 2026, it held approximately 43.37%. The investment was funded from PBM’s existing cash resources.
The milestones were completion of an ibogaine regulatory-readiness documentation package and a manufacturing services agreement between PBM subsidiary Texas Ibogaine Research Corporation and Benuvia, which operates a controlled-substance facility in Round Rock, Texas, registered with the U.S. Drug Enforcement Administration. The agreement is intended to support planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient under cGMP standards, subject to applicable regulatory requirements. PsyLabs is expected to be TIRC’s exclusive U.S. ibogaine supplier under a binding term sheet, subject to a definitive agreement the parties agreed to conclude on or before November 30, 2026. No clinical trial has commenced, and no regulatory application in respect of it has been filed or accepted.
Psyence Biomedical Ltd. issued 1,497,500 common shares to Psyence Labs Ltd. on October 1, 2026, at a deemed issue price of US$6.00 per share under a share-for-share swap. In exchange, Psyence Labs issued 3,473 of its ordinary shares to Psyence Biomed II Corp., the issuer’s wholly owned subsidiary, at the issuer’s direction. The exchange was described as equal in agreed value, with aggregate non-cash consideration of US$8,985,000; no party paid cash.
After the issuance, Psyence Labs beneficially owned 2,643,659 PBM common shares, approximately 49.75% of the 5,314,048 shares outstanding immediately afterward on October 1, 2026. It may be deemed an affiliate and control person. While Psyence Labs and its affiliates own any issuer shares, the agreement restricts specified acquisitions, proxy activity, governance actions and transactions; certain actions require stated consents or approvals. The additional shares also cannot be transferred without an effective registration statement or an available exemption.
PSYENCE BIOMEDICAL LTD. (PBM) is the issuer whose common shares AdvisorShares Trust reported beneficially owning. As of September 30, 2026, the reporting person held 258,538 shares, or 6.78% of the class. It reported sole voting and dispositive power over 258,538 shares and no shared voting or dispositive power.
Psyence Biomedical Ltd. said its wholly owned Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), entered a manufacturing services agreement with Benuvia Operations, LLC for the planned U.S. manufacture of pharmaceutical-grade ibogaine active pharmaceutical ingredient under current Good Manufacturing Practice (cGMP) standards. Benuvia operates a DEA-registered facility of approximately 83,000 square feet in Round Rock, Texas. According to Benuvia, it holds approximately half of the U.S. aggregate production quota for ibogaine; Psyence said information about Benuvia, including its facility and quota, was provided by Benuvia and has not been independently verified.
The partnership builds on TIRC’s binding term sheet with PsyLabs, a significant Psyence shareholder in which Psyence holds an ownership interest, for an exclusive U.S. license, supply and wholesale distribution arrangement. The parties agreed to conclude a definitive agreement on or before November 30, 2026. Benuvia is advancing applications for the import permit and procurement quota required for planned production. Psyence says production timing and scale will be governed primarily by DEA quotas, controlled-substance import requirements and other authorizations. Ibogaine has not been approved for therapeutic use, and its safety and efficacy have not been established through authorized clinical research.
Psyence Biomedical Ltd.’s wholly owned Texas subsidiary, Texas Ibogaine Research Corporation (TIRC), entered a binding term sheet with Psyence Labs Ltd. (PsyLabs) on September 25, 2026. It provides for PsyLabs to grant TIRC exclusive U.S. rights to use PsyLabs’ ibogaine hydrochloride know-how and technical materials to develop, manufacture and commercialize drug candidates. PsyLabs will exclusively supply TIRC; TIRC will be PsyLabs’ exclusive U.S. wholesaler and distributor, while PsyLabs retains rights elsewhere.
TIRC will pay up to approximately US$1.3 million in development and regulatory milestones for the first drug candidate, plus an annual exclusivity fee beginning on the first anniversary of the first FDA approval and creditable against royalties, a low single-digit percentage royalty on each candidate’s net sales, and margin-sharing on TIRC product resales. Exclusivity depends on TIRC sourcing all U.S. ibogaine requirements from PsyLabs, subject to customary supply-failure step-in rights; minimum development and/or sales thresholds are expected in the definitive agreement. That agreement is due by November 30, 2026, or the term sheet lapses; until it takes effect, the term sheet governs its covered matters. PsyLabs is a significant shareholder, Psyence Biomedical holds an ownership interest in PsyLabs, and certain Company management members are PsyLabs affiliates with financial interests, making this a related-party transaction.
PSYENCE BIOMEDICAL LTD. (symbol: PBM) is the issuer of record for a Form 6-K filing submitted to the SEC.
Psyence Biomedical Ltd. (PBM) announced the formation of Texas Ibogaine Research Corporation (TIRC), a Texas-based subsidiary created to coordinate its U.S. ibogaine development activities, including pharmaceutical-grade supply, regulatory engagement and potential clinical development. TIRC is intended to be the dedicated U.S. vehicle for regulated ibogaine development.
Subject to definitive licensing arrangements, TIRC is positioned to hold U.S. rights to pharmaceutical-grade ibogaine developed by PsyLabs, in which Psyence BioMed holds an ownership interest, and will be financed by Psyence BioMed. Jody Aufrichtig will serve as Chief Executive Officer of both Psyence BioMed and TIRC, with Dr. John Thorne as project lead. The company highlights that ibogaine remains a controlled substance and is not approved for therapeutic use, and it outlines regulatory, financing and policy risks that could affect the planned activities.
Psyence Biomedical Ltd. (PBM) has filed a Form F-3 to register for resale up to 1,148,598 Common Shares previously issued in private placements. All shares are being offered by existing holders Psyence Labs Ltd. and Outside The Box Capital Inc.; PBM is not selling any shares and will not receive resale proceeds.
PBM will bear registration and listing expenses, while selling holders cover their own selling costs. The company, an emerging growth company and foreign private issuer, develops nature-derived psilocybin and ibogaine-based therapeutics and holds a significant equity stake in Psyence Labs, its psychedelic API partner.
Psyence Biomedical Ltd. presents an August 2026 investor update describing its clinical-stage focus on nature-derived psychedelic therapeutics for mental health in cancer palliative care, Alcohol Use Disorder, Substance Use Disorder and longevity science. The company highlights having no debt, a strong cash position and two low-cost financing mechanisms, and a vertically integrated platform via a strategic equity stake and supply partnership with PsyLabs for GMP-compliant psilocybin, ibogaine, DMT and mescaline.
The presentation details an Australian Phase IIb trial of NPX-5, a botanical psilocybin, for Adjustment Disorder associated with cancer in the palliative care setting, with 87 patients across three dose arms and a HAM-A primary endpoint at ten weeks, following HREC ethics approval, first patient dosing and FDA Pre-IND feedback. Psyence BioMed outlines an anticipated pathway with topline results planned in H1 2027 and future regulatory interactions, and emphasizes intellectual property efforts and potential data exclusivity. It also describes its ibogaine program, notes a $23.3B projected global palliative care market by 2032 and references a recent U.S. executive order committing $50 million to ibogaine research, framing a supportive external environment for its pipeline.